UK markets closed

Crinetics Pharmaceuticals, Inc. (CRNX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
49.85-1.04 (-2.04%)
As of 02:59PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close50.89
Open51.00
Bid49.77 x 100
Ask50.01 x 100
Day's range49.60 - 51.00
52-week range15.76 - 51.29
Volume449,264
Avg. volume829,049
Market cap3.925B
Beta (5Y monthly)0.63
PE ratio (TTM)N/A
EPS (TTM)-3.69
Earnings date09 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est61.08
  • GlobeNewswire

    Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024

    Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings from Phase 1b/2a ACTH-Dependent Cushing’s Syndrome Trial Data from Phase 3 PATHFNDR 1 and 2 Trials of Paltusotine in Acromegaly will be Presented, in Addition to New Long-Term Safety and Efficacy Findings SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced five abstracts from its clinical development programs, includin

  • GlobeNewswire

    Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

    SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the close of the U.S. financial markets. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, May 9th @ 4:30 PM ETDomestic:1-888-886-7786International:1-416-764-8658Conference ID: 71864759 Participa

  • GlobeNewswire

    Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 121,300 shares of its common stock to ten new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements m